1 426

Cited 2 times in

Salvage chemotherapy with docetaxel and epirubicin for Advanced/Metastatic gastric cancer

DC FieldValueLanguage
dc.contributor.author이동기-
dc.contributor.author이상인-
dc.contributor.author이세준-
dc.contributor.author임재윤-
dc.contributor.author박효진-
dc.contributor.author조재용-
dc.contributor.author백용한-
dc.contributor.author최승호-
dc.contributor.author윤동섭-
dc.contributor.author이관식-
dc.date.accessioned2015-05-19T17:41:22Z-
dc.date.available2015-05-19T17:41:22Z-
dc.date.issued2008-
dc.identifier.issn0030-2414-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/108627-
dc.description.abstractBackground: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8%) patients had a partial response and 12 (37.5%) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47%) and febrile neutropenia in 8 patients (24%). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.-
dc.description.statementOfResponsibilityopen-
dc.format.extent2~8-
dc.relation.isPartOfONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy*-
dc.subject.MESHAdenocarcinoma/secondary-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntibiotics, Antineoplastic/administration & dosage-
dc.subject.MESHAntibiotics, Antineoplastic/adverse effects-
dc.subject.MESHAntineoplastic Agents, Phytogenic/administration & dosage-
dc.subject.MESHAntineoplastic Agents, Phytogenic/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHDisease Progression-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDocetaxel-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHEpirubicin/administration & dosage-
dc.subject.MESHEpirubicin/adverse effects-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHHematologic Diseases/chemically induced-
dc.subject.MESHHumans-
dc.subject.MESHLymphatic Metastasis-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local/drug therapy-
dc.subject.MESHPatient Selection-
dc.subject.MESHPlatinum Compounds/administration & dosage-
dc.subject.MESHSalvage Therapy/methods*-
dc.subject.MESHSeverity of Illness Index-
dc.subject.MESHStomach Neoplasms/drug therapy*-
dc.subject.MESHStomach Neoplasms/pathology*-
dc.subject.MESHTaxoids/administration & dosage-
dc.subject.MESHTaxoids/adverse effects-
dc.subject.MESHTreatment Outcome-
dc.titleSalvage chemotherapy with docetaxel and epirubicin for Advanced/Metastatic gastric cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJae Yun Lim-
dc.contributor.googleauthorJae Yong Cho-
dc.contributor.googleauthorYong Han Paik-
dc.contributor.googleauthorDong Ki Lee-
dc.contributor.googleauthorSang In Lee-
dc.contributor.googleauthorHyo Jin Park-
dc.contributor.googleauthorSe Joon Lee-
dc.contributor.googleauthorKwan Sik Lee-
dc.contributor.googleauthorDong Sup Yoon-
dc.contributor.googleauthorSeung Ho Choi-
dc.identifier.doi10.1159/000120027-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02723-
dc.contributor.localIdA02828-
dc.contributor.localIdA02882-
dc.contributor.localIdA03398-
dc.contributor.localIdA01774-
dc.contributor.localIdA03899-
dc.contributor.localIdA01829-
dc.contributor.localIdA02548-
dc.contributor.localIdA02666-
dc.contributor.localIdA04102-
dc.relation.journalcodeJ02416-
dc.identifier.eissn1423-0232-
dc.identifier.pmid18332648-
dc.identifier.urlhttp://www.karger.com/Article/FullText/120027-
dc.subject.keywordGastric cancer-
dc.subject.keywordDocetaxel chemotherapy-
dc.contributor.alternativeNameLee, Dong Ki-
dc.contributor.alternativeNameLee, Sang In-
dc.contributor.alternativeNameLee, Se Joon-
dc.contributor.alternativeNameLim, Jae Yun-
dc.contributor.alternativeNamePark, Hyo Jin-
dc.contributor.alternativeNameCho, Jae Yong-
dc.contributor.alternativeNamePaik, Yong Han-
dc.contributor.alternativeNameChoi, Seung Ho-
dc.contributor.alternativeNameYoon, Dong Sup-
dc.contributor.alternativeNameLee, Kwan Sik-
dc.contributor.affiliatedAuthorLee, Dong Ki-
dc.contributor.affiliatedAuthorLee, Sang In-
dc.contributor.affiliatedAuthorLee, Se Joon-
dc.contributor.affiliatedAuthorLim, Jae Yun-
dc.contributor.affiliatedAuthorPark, Hyo Jin-
dc.contributor.affiliatedAuthorCho, Jae Yong-
dc.contributor.affiliatedAuthorPaik, Yong Han-
dc.contributor.affiliatedAuthorYoon, Dong Sup-
dc.contributor.affiliatedAuthorLee, Kwan Sik-
dc.contributor.affiliatedAuthorChoi, Seung Ho-
dc.rights.accessRightsnot free-
dc.citation.volume73-
dc.citation.number1-2-
dc.citation.startPage2-
dc.citation.endPage8-
dc.identifier.bibliographicCitationONCOLOGY, Vol.73(1-2) : 2-8, 2008-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.